Sotatercept Safety and Effects on Hemoglobin, Bone, and Vascular Calcification

Sotatercept Safety and Effects on Hemoglobin, Bone, and Vascular Calcification

Introduction: Patients with end-stage kidney disease (ESKD) exhibit anemia, chronic kidney disease‒mineral bone disorder (CKD–MBD), and cardiovascular disease. The REN-001 and REN-002 phase II, multicenter, randomized studies examined safety, tolerability, and effects of sotatercept, an ActRIIA-IgG1...

Full description

Bibliographic Details
Main Authors: Daniel W. Coyne, Hem N. Singh, William T. Smith, Ana Carolina Giuseppi, Jamie N. Connarn, Matthew L. Sherman, Frank Dellanna, Hartmut H. Malluche, Keith A. Hruska
Format: Article
Language:English
Published: Elsevier 2019-11-01
Series:Kidney International Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2468024919314445

Internet

http://www.sciencedirect.com/science/article/pii/S2468024919314445

Similar Items